



MARKET ANNOUNCEMENT

- **34 USCOM units ordered by Spacelabs Healthcare**

Thursday, 5 March 2009: Uscom (ASX Code: UCM) today informed shareholders that its new partner Spacelabs Healthcare has placed orders for a further 34 USCOM units. Some of the units will be used to support Spacelabs marketing activity whilst the remainder are for inventory ready to meet expected customer demand over the coming months. The units are to be delivered over the next four months.

Uscom CEO, Mr. Paul Butler said "These orders from Spacelabs demonstrate the enthusiasm with which they are taking the USCOM 1A to market and their confidence in the product. I have been involved in the Spacelabs product launch over the past two months and I am pleased with the interest that has been generated in the market."

Mr Rob Phillips, Executive Chairman and Director of Clinical Science said "This is further evidence of the commitment that Spacelabs has for taking USCOM to market. Uscom will be working closely with them to ensure a successful partnership."

About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.

The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom contact

Paul Butler
Chief Executive Officer
Office: +1 646 379 3278
paul.butler@uscom.com.au

Rob Phillips
Executive Chairman
Office: 02 9247 4144
rob@uscom.com.au